Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma

BACKGROUND: The monoclonal antibody zolbetuximab (formerly IMAB362), which is being developed as a potential treatment for gastric cancer (GC), targets Claudin 18.2 (CLDN18.2), a GC biomarker. This study aimed to determine the prevalence of CLDN18.2 in primary tumors and lymph node (LN) metastases o...

Descripción completa

Detalles Bibliográficos
Autores principales: Rohde, Christoph, Yamaguchi, Rin, Mukhina, Svetlana, Sahin, Ugur, Itoh, Kyogo, Türeci, Özlem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6792344/
https://www.ncbi.nlm.nih.gov/pubmed/31087075
http://dx.doi.org/10.1093/jjco/hyz068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6792344/
https://www.ncbi.nlm.nih.gov/pubmed/31087075
http://dx.doi.org/10.1093/jjco/hyz068

Ejemplares similares